For Chronic Lymphocytic Leukemia (CLL) patients, and their families, the number of options for treatment has increased significantly over the last decade. Many newer treatments for CLL are targeted therapies designed to interfere with specific cellular pathways involved in cancer cell growth. There are several different treatments currently available which target the BTK pathway. Among the two newest treatments, which have gained a lot of attention from the medical community, are Jaypirca and Brukinsa.
For patients and their families exploring CLL treatment options, comparing jaypirca vs brukinsa will be an important part of understanding the potential of each individual targeted therapy as well as their overall place in managing CLL.
Understanding the Role of BTK Inhibitors in CLL
Research has identified Bruton’s Tyrosine Kinase (BTK) as a protein crucial for the growth, survival and resistance to apoptosis of CLL cells. BTK is involved in the signaling of cells, enabling them to grow and divide. Targeted therapies, known as BTK inhibitors, block BTK signals, thus stopping the growth of the CLL cancer cells and slowing disease progression. These drugs represent a targeted approach used in the management of CLL. As opposed to traditional chemotherapy, BTK inhibitors aim to specifically target cancer cells and offer patients with several treatment options.
BTK inhibitors are a form of targeted therapy for the treatment of CLL and work by halting signals for cancer cell growth and survival. By blocking the action of BTK, these drugs slow down cancer cell growth and/or cause them to die. Because these drugs target specific signaling pathways, their safety profiles differ from those of traditional chemotherapy. BTK inhibitors are a major advancement in the treatment of CLL and are used as a first-line or subsequent therapy for patients with this disease.
Like other targeted therapies for CLL, Jaypirca and Brukinsa target the BTK protein in different ways, in order to stop the leukemia cells from growing and dividing.
What Is Brukinsa?
Brukinsa, (zanubrutinib) is a BTK inhibitor that consistently and sustainably inhibits the BTK signaling pathway. The drug has been approved and is being marketed for the treatment of patients with mantle cell lymphoma as well as for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 1 prior therapy. Brukinsa has demonstrated complete and partial response rates in clinical studies of patients with CLL. Brukinsa may be used as part of an ongoing treatment approach based on individual clinical circumstances, in addition to being used as a treatment after other therapies have failed to provide a satisfactory outcome.
Brukinsa (zanubrutinib) is a BTK inhibitor used for the treatment of CLL and other cancers of the blood. In clinical trials, Brukinsa induced high rates of complete and partial remission in patients with CLL and showed long-lasting control of the disease. The drug was developed to provide optimal inhibition of BTK while being safe and effective for a wide variety of patients.
Brukinsa is typically used as part of a long-term strategy to manage CLL for individual patients. It is important that individual treatment decisions are made by patients in conjunction with their treating doctor taking into account a number of factors including the patient’s overall health, treatment objectives and CLL characteristics.
What Is Jaypirca?
Jaypirca (pirtobrutinib) is a next generation BTK inhibitor. Unlike other covalent BTK inhibitors such as Brukinsa, Jaypirca is a non-covalent BTK inhibitor. It acts on the BTK protein in a unique way and is currently under investigation for a variety of treatment scenarios for CLL.
The non-covalent binding to BTK of pirtobrutinib (Jaypirca) is another mechanism to inhibit the BTK signaling pathway and researchers are continuing to evaluate the role of this drug in treating patients with CLL in various treatment settings including as a therapy for patients with specific characteristics of their disease. When comparing jaypirca vs brukinsa, it is worth noting that each is intended to be used for different purposes within a CLL patient’s treatment.
Key Differences to Consider
While both Jaypirca and Brukinsa are BTK inhibitors, there are significant differences with both how they interact with BTK and how they could potentially be used in a patient’s treatment.
The first consideration is whether the patient is a treatment naïve patient just diagnosed with CLL or is a patient that has received previous treatment for their CLL. As a general practice, different treatments are used for different stages of disease in CLL patients. There is an increasing push towards treating cancer on an individual basis and tailoring the treatment for the individual’s specific cancer. No longer can a single treatment be given to all patients with a certain type of cancer. As a result, the comparison between Jaypirca and Brukinsa is typically very individualized and does not usually compare one treatment to another in a broad sense as to which is better.
The Importance of Clinical Evidence
The decision to recommend treatment for CLL is based on many studies of CLL patients and the resulting data regarding the efficacy and safety of the drug as well as the duration of the treatment effects and the long term effects of the treatment.
By understanding the clinical data that have been gathered in trials with CLL patients who are on treatment with pirtobrutinib (Jaypirca), other drugs for the treatment of CLL and the specific characteristics of a patient’s disease, their previous treatment, overall health, and more, a patient and their team of healthcare providers can come up with the best strategy for the specific situation of a particular patient. It is important for patients with CLL and their families to be familiar with the clinical evidence supporting the different therapies and how that evidence can be used in making a treatment decision.
Factors That Influence Treatment Decisions
Several factors may be considered when evaluating treatment options for CLL, including:
- Disease stage and progression
- Previous treatment history
- Genetic and molecular characteristics of the leukemia
- Overall health and medical history
- Potential treatment goals
- Lifestyle considerations and patient preferences
No single aspect of CLL affects choice of therapy. The process is more complex and multi-faceted than that. All of the following factors can influence the therapeutic choice in individual patients with CLL: the stage and clinical behavior of the patient’s disease, prior therapies, molecular and genetic features of the patient’s leukemic cells, other aspects of the patient’s medical history and overall health status, and the goals and expectations that the patient has for his or her therapeutic program. In the end, choices are typically made on a case-by-case basis, considering all relevant factors in the individual patient’s unique clinical circumstances.
Why Personalized Treatment Matters
Everyone’s situation is different and each patient can have slow growing CLL for many years and require no treatment at all or could need treatment quickly due to the severity of their disease. Also, there can be big differences in the genetic make-up of CLL cells from one patient to another. This can impact on the behavior of a patient’s disease and how it will be treated.
As with any cancer treatment, when looking at jaypirca vs brukinsa you must remember that both treatments are best given on a case-by-case basis and should be considered within the context of the patient’s individual clinical profile. What works for one person with CLL may not work for another. Using the results from diagnostic tests, the healthcare provider’s clinical experience and current research findings, the healthcare provider can develop a treatment plan that best fits the individual’s needs.
Questions Patients Should Ask Their Healthcare Team
If patients are considering several different options, there are several key questions that they should ask about each of the available options. For example:
- Why is this treatment being recommended?
- What clinical evidence supports this approach?
- How will treatment effectiveness be monitored?
- What side effects should I expect?
- How might treatment affect my daily routine?
- What alternative or future treatment options are available.
Talking through all the options and reasons for a particular choice can give patients a better understanding of their decisions and allow them to play a more active role in their care.
Conclusion
Recently introduced are advanced BTK inhibitors Jaypirca and Brukinsa, for the treatment of CLL or other cancers. These BTK inhibitors are examples of targeted or precision cancer therapies.
It is also important to note that when weighing the option of jaypirca vs brukinsa for your CLL treatment, it is best to not compare them in a vacuum, but to discuss and see how they can play a role in your overall treatment for CLL. It is best to understand how each can be used for your specific case, based on the rest of your history and how your CLL has progressed to date, and make a treatment decision that fits your goals for your CLL treatment.
